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The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the 
focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA 
approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 anti-
bodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/
PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, 
expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to 
enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 
expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the 
impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ 
T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker 
in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor 
cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade 
therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to 
antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the 
context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well 
as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.
Keywords: immunotherapy, programmed death-1:programmed death-ligand 1 blockade, B7-H1 (programmed 
death-ligand 1), T cells, CTL, tumor
iNTRODUCTiON
Programmed death-ligand 1 (PD-L1, also referred to as B7-H1 or CD274) is constitutively expressed by 
cells of the myeloid lineage, including macrophages and dendritic cells (1–3). Cells from the lymphoid, 
endothelial, and epithelial lineages, including cancer cells from these lineages, express PD-L1 upon activa-
tion by IFN-γ and TNF-α (4). Naïve murine T cells express low levels of PD-L1, while naïve human T cells 
do not; however, both murine and human T cells express high levels of PD-L1 upon antigen stimulation 
(3, 5). PD-L1 has been extensively characterized as a ligand for PD-1, an inhibitory receptor expressed by 
activated CD8+ T cells. Upon interaction with PD-L1, PD-1 counteracts signaling downstream of T cell 
receptor (TCR) ligation and CD28 co-stimulation (6). When PD-L1 interacts with PD-1, the immuno-
receptor tyrosine-based inhibitory motifs and immunoreceptor tyrosine-based switch motifs on the 
Abbreviations: APC, antigen-presenting cells; B7-H1, B7 homolog 1; Bim, Bcl-2-like protein 11; HCV, hepatitis C virus; HIF-
1α, hypoxia-inducible factor-1α; LCMV, lymphocytic choriomeningitis virus; MDC, myeloid dendritic cells; MDSC, myeloid-
derived suppressor cell; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; sPD-L1, soluble PD-L1.
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intracellular domain of PD-1 become phosphorylated. This 
recruits the phosphatases SHP-1 and SHP-2 to the intracellular 
domain of PD-1, which is in the vicinity of the TCR. SHP-1 and 
SHP-2 dephosphorylate the immunoreceptor tyrosine-based 
activation motifs of the TCR, thus dampening the signaling 
downstream of the TCR (7). By inhibiting TCR signaling, PD-1 
prevents the activation of the PI3K/Akt and c-Myc pathways, and 
inhibits cell survival, proliferation, and cytokine production by 
CD8+ T cells (8). It is important to note that PD-L1 also interacts 
with CD80 (B7-1), which is expressed on the surface of CD8+ 
T  cells. The signaling events that are initiated downstream of 
CD80 are still under investigation, but have been shown to have 
similar effects on CD8+ T cell function as signaling downstream 
of the PD-L1/PD-1 interaction (9–11).
The rationale for PD-L1/PD-1 checkpoint blockade therapies 
is to block the PD-L1/PD-1 interaction between tumor cells 
and CD8+ T cells with an antibody to allow for CD8+ T cells to 
overcome PD-1 inhibitory signaling and eliminate the tumor cells. 
FDA-approved anti-PD-1 antibodies include pembrolizumab and 
nivolumab. Currently pembrolizumab is approved for treatment 
of metastatic melanoma, both squamous and non-squamous non-
small cell lung cancer (NSCLC), head and neck squamous-cell 
carcinoma, and Hodgkin’s lymphoma, and nivolumab is approved 
for treatment of metastatic melanoma, both squamous and non-
squamous NSCLC, and renal-cell carcinoma. FDA-approved 
anti-PD-L1 antibodies include durvalumab, atezolimuab, and 
avelumab. Currently, durvalumab is approved for treatment of 
urothelial carcinoma, atezolimuab is approved for treatment of 
NSCLC and urothelial carcinoma, and avelumab is approved 
for treatment of Merkel cell carcinoma. PD-L1/PD-1 checkpoint 
blockade treatments yield durable responses for a significant num-
ber of patients, but many patients exhibit variable responses or no 
response to the treatments (12–24). These drugs are all in ongoing 
clinical trials to determine their use for additional tumor types.
There are also efforts underway to identify biomarkers that can 
be used to predict which patients will likely respond to PD-L1/
PD-1 checkpoint blockade therapies. Logically, the expression of 
PD-L1 by a patient’s tumor cells is the focus of much of these 
efforts and will be discussed below. Numerous other biomarkers 
have been identified as useful tools for distinguishing “non-
responders” from “responders” for PD-L1/PD-1 checkpoint 
blockade therapy. The presence of circulating PD-1+ CD8+ T cells 
that express the pro-apoptotic molecule Bim was predictive of 
clinical benefit in patients with metastatic melanoma that were 
treated with anti-PD-1 checkpoint blockade therapy (25). When 
PD-1+ CD8+ T cells interact with PD-L1, the expression of Bim 
is increased (11), therefore Bim expression by circulating PD-1+ 
CD8+ T cells is associated with CD8+ T cells that have encountered 
PD-L1 and would be reinvigorated by PD-L1/PD-1 checkpoint 
blockade. PD-1+ CD8+ T cells that are reinvigorated by PD-L1/
PD-1 checkpoint blockade depend on CD28 co-stimulation 
for proliferation, thus the expression of CD28 by circulating 
PD-1+ CD8+ T  cells has also been identified as a potential 
biomarker for predicting responses to PD-L1/PD-1 checkpoint 
blockade therapy (26). PD-L1 is classically characterized as 
membrane-bound, but a soluble form of PD-L1 (sPD-L1) also 
exists and high serum levels of sPD-L1 are associated with poor 
prognosis in renal-cell carcinoma and multiple myeloma (27, 28). 
Increased levels of sPD-L1 in the circulation of patients treated 
with PD-L1/PD-1 checkpoint blockade for malignant melanoma 
predicted a greater chance of partial response to therapy when 
assayed at 5  months after initiation of treatment (29). Tumors 
with deficiency in the mismatch-repair pathway for DNA repair 
or with high microsatellite instability are highly immunogenic 
and patients with tumors having either of these characteristics 
are more likely to respond to PD-L1/PD-1 checkpoint blockade 
therapy (30). These types of tumors, regardless of tissue of origin, 
generate multitudes of novel antigens due to their high mutation 
burden, making them ideal targets for CD8+ T  cell responses 
reinvigorated by PD-L1/PD-1 checkpoint blockade therapy. The 
FDA recently approved pembrolizumab as a treatment for any 
unresectable or metastatic solid tumor that is mismatch repair 
deficient or has high microsatellite instability. This is the first 
FDA-approved treatment that is based on a biomarker rather 
than on the tissue of origin of the tumor.
As mentioned earlier, PD-L1 expression by tumor cells has 
been characterized as a biomarker for predicting patient out-
comes to PD-L1/PD-1 checkpoint blockade therapy. Multiple 
studies have shown that PD-L1 expression is predictive of 
positive responses to PD-L1/PD-1 checkpoint blockade therapy 
(31–33). However, patients with PD-L1 negative tumors often 
exhibit positive responses to PD-L1/PD-1 checkpoint blockade 
therapies (20). Despite these findings, the FDA has approved 
PD-L1 biomarker tests as companions to nivolumab for treat-
ment of NSCLC, pembrolizumab for treatment of NSCLC, and 
atezolimuab for treatment of urothelial carcinoma. Some of the 
unpredictability of responses to PD-L1/PD-1 checkpoint block-
ade therapies may be due to the heterogeneity and dynamics of 
PD-L1 expression by tumor cells and immune cells, including 
dendritic cells and CD8+ T cells (34, 35). Recent reports indicate 
that PD-L1 expressed by both tumor cells and non-tumor host 
cells contributes to the efficacy of PD-L1/PD-1 checkpoint 
blockade therapies in preclinical models (36, 37). It is essential 
to consider the role of the PD-L1/PD-1 interaction outside of the 
tumor setting in order to gain a better understand of the effects 
of PD-L1/PD-1 checkpoint blockade therapies.
The PD-L1/PD-1 interaction is involved during the initial 
activation or priming phase of naïve CD8+ T  cells as PD-L1 
is expressed on the surface of dendritic cells in the spleen and 
lymph nodes where T cell priming takes place, and PD-1 expres-
sion by CD8+ T cells is upregulated early on during the priming 
phase (38–40). In this review, we will consider how PD-L1/
PD-1 checkpoint blockade therapies affect the priming phase of 
antitumor CD8+ T  cell responses. Activated CD8+ T  cells also 
express PD-L1, and it has been demonstrated that this expres-
sion of PD-L1 plays a role in the survival of activated CD8+ 
T  cells during the contraction phase of an immune response 
(41, 42). Accordingly, the CD8+ T cell intrinsic role for PD-L1/
PD-1 signaling will also be examined. Finally, the role of PD-L1 
expressed by tumor cells in regulating CD8+ T  cell antitumor 
immune responses will be considered. These interactions are 
summarized in Figure 1.
FigURe 1 | The programmed death ligand-1 (PD-L1) (B7-H1) pathway in 
regulation of T cell responses to tumors. Once naïve T cells encounter 
cognate antigen presented by antigen-presenting cells (APC), they are 
primed and express PD-1 and CD80, two receptors of PD-L1. PD-1 once 
engaged by its ligand recruits the phosphatase SHP-2 to inhibit AKT 
activation by preventing CD28-mediated activation of PI3K. Along with CD80, 
PD-1 suppresses T cell expansion, and limits differentiation to memory cells 
by upregulation of Bim. Following expansion, T cells undergo contraction in 
which PD-L1 expressed by activated T cells provides pro-survival signals to 
T cells by upregulating Bcl-xl and inhibiting p38 MAPK activation. After 
arriving at the tumor site, PD-L1 expressed by tumor cells or tumor-
associated macrophages or MDSCs suppresses the function of tumor-
reactive T cells by inducing either apoptosis or exhaustion. MDSC, 
myeloid-derived suppressor cells; Bim, Bcl-2-like protein 11.
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THe ROLe OF PD-L1 eXPReSSeD BY 
DeNDRiTiC CeLLS
Both PD-1 and CD80 are expressed on CD8+ T cells early during 
activation and priming by dendritic cells (43–45). Additionally, 
dendritic cells express cell-surface PD-L1 upon activation by 
various toll-like receptor ligands (40). In considering how PD-L1/
PD-1 checkpoint blockade therapies influence antitumor CD8+ 
T cell responses, it is important to first consider the role of PD-L1 
during the priming phase of an immune response. During this 
phase, naïve CD8+ T cells that are reactive against tumor antigens 
get activated in secondary lymphoid organs and undergo impor-
tant changes in differentiation that will affect the resulting effector 
and memory antitumor CD8+ T cell responses. Several studies 
have demonstrated that PD-L1 signaling during the priming 
phase limits CD8+ T cell responses, so PD-L1/PD-1 checkpoint 
blockade therapies likely work in part by enhancing CD8+ T cell 
responses by influencing events during the priming phase of an 
antitumor immune response.
In order to generate an effective antitumor CD8+ T cell response, 
the signals provided by dendritic cells during the priming phase 
must initiate rapid proliferation of antitumor CD8+ T  cells as 
well as orchestrate differentiation programs that will give rise to 
effector CD8+ T cells and memory CD8+ T cells. Several groups 
have independently demonstrated that CD8+ T  cells exhibit 
increased proliferation when primed in the absence of PD-L1 
signaling, indicating that PD-L1 signaling serves to restrict the 
proliferative capacity of CD8+ T cells during activation. Benedict 
et al. demonstrated that dendritic cells infected with CMV had 
high surface expression of PD-L1 and were unable to induce pro-
liferation of antigen-specific CD8+ T cells. Including an antibody 
against PD-L1 in their in vitro priming model largely restored the 
ability of CMV-infected dendritic cells to induce proliferation of 
antigen-specific CD8+ T cells (46). In an in vivo priming model, 
we found that the numbers of antigen-specific CD8+ T  cells 
significantly increased in animals immunized with activated 
dendritic cells that lacked PD-L1 expression as compared to acti-
vated dendritic cells with intact PD-L1 expression (40). Using an 
HSV-1 model, Channappanavar et al. demonstrated that systemic 
delivery of anti-PD-L1 antibody 1 day prior to HSV-1 infections 
allowed for increased proliferation of antigen-specific CD8+ 
T cells as compared to mice infected with HSV-1 in the absence 
of anti-PD-L1 treatment (47). Together these studies indicate 
that systemic treatment with PD-L1/PD-1 checkpoint blockade 
antibody therapy should result in increased proliferation of CD8+ 
T cell responses being primed in patients.
Differentiation of effector and memory CD8+ T cells occurs 
during the priming phase through a mechanism termed program-
ming, in which naïve CD8+ T cells respond to external stimuli, 
including TCR signaling, co-stimulatory signaling, and cytokine 
signaling (38). The combination of these stimuli that a naïve 
CD8+ T cell encounters will determine the outcome of program-
ming and have long-lasting impacts on the resulting effector and 
memory populations (48). In order to generate a potent effector 
and memory CD8+ T  cell responses, naïve CD8+ T  cells must 
encounter a cognate TCR stimulus in the context of positive co-
stimulatory signals and pro-inflammatory cytokines (49). It has 
been well established that PD-L1 signaling is integrated during 
CD8+ T cell priming to restrain the differentiation of effector and 
memory CD8+ T cells.
Effector CD8+ T cells primed in the absence of PD-L1 signaling 
exhibit increased cytokine production and enhanced cytotoxic 
activity as compared to CD8+ T  cells primed in the presence 
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of PD-L1 signaling (40, 44, 45, 47, 50). Immunization of mice 
with PD-L1 deficient dendritic cells pulsed with OVA peptide 
resulted in effector CD8+ T cells that secreted increased levels of 
IFN-γ and were better able to control B16-OVA tumor growth as 
compared to effector CD8+ T cells primed by dendritic cells with 
intact PD-L1 expression (40). Similar results were found when 
anti-PD-L1 antibody was used to block PD-L1 signaling by the 
injected dendritic cells in this same study. CD8+ T cells activated 
in the absence of PD-L1 signaling had significantly increased 
production of IFN-γ (50). Using an HSV-1 infection model, 
Channappanavar et  al. showed that blocking PD-L1 signaling 
during the priming phase resulted in effector CD8+ T cells with 
increased granzyme B exocytosis upon ex vivo antigen stimula-
tion. Mice injected with anti-PD-L1 prior to HSV-1 infection also 
demonstrated significantly lower viral load 6 days postinfection 
(47). Using a brief in vitro priming model to activate OT-I CD8+ 
T  cells with OVA-presenting dendritic cells with either intact 
or deficient PD-L1 expression, it was demonstrated that CD8+ 
T cells primed in the absence of PD-L1 secreted increased levels 
of IFN-γ and exhibited increased in vivo cytotoxic activity (45). 
These studies show that PD-L1 signaling during the priming 
phase influences the differentiation of effector CD8+ T cells by 
restraining the acquisition of effector functions.
During the priming phase, PD-L1 also controls differentiation 
of the resulting population of memory CD8+ T cells (51). In the 
same HSV-1 infection model as described above, Channappanavar 
et  al. investigated the influence of PD-L1 signaling during 
priming on the resulting antigen-specific CD8+ T cell memory 
population. PD-L1 blocking antibody or isotype control antibody 
was injected 1 day prior and 3 days after HSV-1 infection. Mice 
were re-challenged with HSV-1 32 days after infection and CD8+ 
T cell recall responses were assayed on day 4 after re-infection. In 
mice that primed an anti-HSV-1 CD8+ memory T cell response 
in the absence of PD-L1 signaling, the memory recall response 
exhibited increased antigen-specific secretion of IFN-γ and 
granzyme B (47). Similar data were generated using an in vivo 
priming model and B16-OVA tumor challenge in which wild-
type mice were injected with naïve OT-I CD8+ T cells (CD45.2+) 
and OVA-presenting activated bone marrow-derived dendritic 
cells that were either wild type or PD-L1 deficient. On day 30 after 
the injection of the naïve CD8+ T cells and activated dendritic 
cells, the mice were challenged with an intravenous injection of 
B16-OVA tumor cells. The recall response of the CD45.2+ T cells 
was analyzed 4  days after tumor challenge. In mice that had 
PD-L1-deficient dendritic cells during the priming phase, there 
was an increase in IFN-γ in the lungs as compared to mice that 
received dendritic cells with intact PD-L1 (45). Together these 
studies demonstrate that PD-L1 signaling is integrated during the 
priming phase and limits the differentiation of memory CD8+ 
T cell populations.
An additional level of regulation during T  cell priming is 
ligand-induced TCR down-modulation, in which TCRs that 
have engaged with cognate peptide–MHC are internalized and 
downstream signaling is terminated (52, 53). Karwacz et al. inves-
tigated the influence of PD-L1/PD-1 signaling on the process of 
TCR down-modulation during priming. They knocked-down 
PD-L1 expression in bone marrow-derived dendritic cells using 
lentivirus-delivered short hairpin RNA and found that in the 
absence of PD-L1 signaling during the priming phase (both 
in  vitro and in  vivo) CD8+ T  cells exhibited decreased TCR 
down-modulation as compared to CD8+ T cells primed by bone 
marrow-derived dendritic cells with PD-L1 expression intact (50). 
They went on to show that when PD-L1 is absent during priming, 
CD8+ T cells failed to upregulate the E3 ubiquitin ligase Cbl-b, 
which has been demonstrated to contribute to ligand-induced 
TCR down-modulation (54–56). These results were replicated 
when antibodies blocking either PD-L1 or PD-1 were included 
in their in vitro priming model, thus implicating a role for PD-L1 
signaling in TCR down-modulation. In addition to membrane 
expression of PD-L1 by dendritic cells, a sPD-L1 produced by 
activated human dendritic cells may provide a non-proximal 
regulation of circulating PD-1+ or CD80+ T cells by dendritic cells 
(57). Altogether these studies indicate that blockade of PD-L1 
signaling during the priming phase of CD8+ T  cells would be 
beneficial for priming antitumor immune responses.
THe ROLe OF PD-L1 eXPReSSeD BY 
eFFeCTOR CD8+ T CeLLS
CD8+ T cells upregulate expression of PD-L1 upon antigen stimu-
lation, so it is important to consider how PD-L1/PD-1 checkpoint 
blockade therapies influence effector CD8+ T cells. Several studies 
have reported a T cell intrinsic pro-survival/antiapoptotic role for 
PD-L1 expressed by effector CD8+ T cells; therefore, it is likely 
that PD-L1/PD-1 checkpoint blockade therapies have deleteri-
ous effects on the functions of effector CD8+ T cells. Since the 
goal of PD-L1/PD-1 checkpoint blockade therapies is to enhance 
CD8+ T cell killing of tumor cells, it is essential that we more fully 
understand the role of PD-L1 expressed by effector CD8+ T cells.
Using an OVA protein immunization model of antigen stimu-
lation in mice, Pulko et al. demonstrated that PD-L1 expressed 
by effector CD8+ T cells is required for their survival during the 
contraction phase of an immune response (41). Six days following 
immunization with OVA protein and poly(I:C), PD-L1-deficient 
CD8+ T  cells exhibited increased contraction and enhanced 
susceptibility to being killed by other CD8+ T cells. Additionally, 
upon in vitro antigen stimulation, PD-L1-deficient CD8+ T cells 
expressed lower levels of Bcl-xL, an antiapoptotic molecule. Saha 
et al. demonstrated similar findings in a mouse graft-versus-host 
disease model (58). PD-L1-deficient allogeneic donor CD8+ 
T cells exhibited decreased expansion and survival 5 days after 
transfer as compared to wild-type allogeneic donor CD8+ T cells. 
The impaired survival of PD-L1-deficient CD8+ T cells was deter-
mined to be due to lower expression levels of the pro-survival 
proteins Bcl-xL and CD127. Additionally, PD-L1-deficient allo-
geneic donor CD8+ T cells had diminished cytokine production 
and impaired metabolic activity, including decreased glycolytic 
capability, decreased oxidative phosphorylation, and decreased 
fatty acid oxidation as compared to wild-type allogeneic donor 
CD8+ T cells. Another report confirmed the decreased expres-
sion of Bcl-xL in PD-L1-deficient CD8+ T  cells and proposed 
that the interaction of PD-L1 with CD80, both expressed by 
CD8+ T cells, contributes to CD8+ T cell survival and expansion 
5Gibbons Johnson and Dong PD-L1 in Tumor Immunity
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 961
(59). This pro-survival/antiapoptotic role for PD-L1 expressed 
by CD8+ T cells could explain the deleterious effects of PD-L1 
blockade as reported in Listeria monocytogenes infection models 
(60–62) and could also explain the variable patient responses to 
PD-L1/PD-1 checkpoint blockade therapy. The role of PD-L1 
expressed by CD8+ T  cells within a tumor setting needs to be 
further elucidated. It was recently demonstrated that certain anti-
PD-L1 blocking antibodies are capable of inducing apoptosis of 
effector PD-L1+ CD8+ T cells through activating the p38 MAPK 
pathway, and are thus ineffective as tumor treatments (42). Since 
this potential agonist effect of anti-mouse PD-L1 antibody was 
observed in preclinical models, whether therapeutic antibodies to 
human PD-L1 would have similar agonist effects warrants further 
investigation.
THe ROLe OF PD-L1 eXPReSSeD BY 
TUMOR CeLLS AND TUMOR-
ASSOCiATeD SUPPReSSOR CeLLS
Effector CD8+ T  cells primed against tumor antigens have the 
potential to eliminate tumor cells, but have failed to do so in 
patients with clinically diagnosed cancer. The tumor microenvi-
ronment is inhospitable to effector CD8+ T cells with numerous 
overlapping mechanisms in place to inhibit CD8+ T cell responses, 
including the cell-surface expression of PD-L1 by many tumor 
types (63). Some tumor cells intrinsically express cell-surface 
PD-L1 while other tumor cells express PD-L1 in response to 
inflammatory cytokines, a mechanism termed adaptive resist-
ance (64). If a tumor cell that expresses PD-L1 on its surface 
encounters antitumor CD8+ effector T cells that expresses PD-1 
or CD80, then the tumor cell will initiate signaling downstream 
of PD-1 and CD80. Here, we will discuss the outcomes of this 
encounter.
Effector CD8+ T cells isolated from tumor microenvironments 
exhibit an exhausted phenotype characterized by high surface 
expression of PD-1 and impaired responses to antigenic stimuli 
(65–68). It has recently been determined that PD-1 signaling 
does not initiate differentiation of the exhausted phenotype in 
CD8+ T cells (69), but PD-1 signaling is widely accepted to be the 
most important receptor involved in maintaining the exhausted 
phenotype (70). Most of the studies regarding PD-L1/PD-1 
signaling in CD8+ T cell exhaustion have been done using mod-
els of chronic viral infection, but these findings are applicable 
to tumor settings. Blocking PD-1 signaling has been shown in 
several models of chronic viral infections to restore antigenic 
sensitivity of exhausted CD8+ T cells. Barber et al. infected mice 
with lymphocytic choriomeningitis virus clone 13 then treated 
mice with anti-PD-L1 antibody 23–37 days postinfection. They 
found significantly decreased viral loads in mice treated with 
anti-PD-L1 and increased levels of IFN-γ production by CD8+ 
T cells in response to viral antigen stimulation (71). These results 
were quickly corroborated in HIV, Hepatitis C virus (HCV), and 
Hepatitis B virus infections (72–78). Blocking PD-L1 signaling 
in mouse tumor models has also been shown to restore effector 
antitumor CD8+ T  cell responses leading to tumor regression 
and durable antitumor protection (40, 79, 80). Tumor cells 
also produce a sPD-L1 that can be detected in the plasma of 
cancer patients and suppresses T  cell functions (27). Recently, 
the increase of sPD-L1 in melanoma patients has been proposed 
as a potential mechanism of resistance to immune checkpoint 
blockade therapy (29, 81).
In addition to restraining effector functions in CD8+ T cells, 
PD-L1 signaling also induces apoptosis of effector CD8+ T cells (2, 
70, 73). Signaling downstream of PD-1 has been shown to inhibit 
the CD28-mediated upregulation of the pro-survival molecule 
Bcl-xL (8). HIV-specific CD8+ T cells have been shown to express 
decreased levels of Bcl-xL and exhibit increased susceptibility to 
apoptosis that is correlated to increased levels of PD-1 surface 
expression (73, 82). PD-L1 co-stimulation induced increased 
expression of the pro-apoptotic molecule Bim by effector CD8+ 
T cells in an in vitro model (11). Accordingly, PD-L1 co-stimulation 
failed to induce apoptosis in Bim-deficient effector CD8+ T cells. 
Larrubia et al. also reported increased Bim expression levels in 
CD8+ T cells with high PD-1 expression levels in patients with 
chronic HCV infection (83). Additionally, PD-1+ CD8+ T  cells 
isolated from B16 tumors in mice express higher levels of Bim as 
compared to PD-1− CD8+ T cells isolated from the same tumor 
(84). This same trend was observed in peripheral-blood tumor-
reactive CD8+ T cells from melanoma patients. Through in vitro 
PD-L1/PD-1 blockade studies, Dronca et al. demonstrated that 
the anti-PD-1 antibodies currently used clinically (nivolumab and 
pembrolizumab) decrease Bim expression levels in human PD-1+ 
CD8+ T cells in patients who respond to treatment. Importantly, 
it was demonstrated that PD-L1 induced increased expression of 
Bim by signaling through both PD-1 and CD80. If the interaction 
between either PD-L1 and PD-1 or PD-L1 and CD80 was blocked 
using antibodies, then the PD-L1-induced increase in Bim levels 
was lost (11). Related to this, it was found that CD80-deficient 
CD8+ exhibited an enhanced memory response to immunization 
as compared to wild-type CD8+ T cells that were co-transferred 
into a naïve host, again indicating that PD-L1 signaling through 
CD80 on CD8+ T  cells restrains the memory response (11). 
Blockade of PD-L1 may also blunt pro-survival signal of PD-L1 to 
tumor cells per se since it has been reported that reverse signaling 
of PD-L1 promotes tumor survival and growth (85, 86).
Effector CD8+ T cells require a massive amount of energy to 
maintain rapid proliferation and effector functions. Naïve CD8+ 
T  cells utilize oxidative phosphorylation, but upon activation 
CD8+ T cells make a metabolic switch and primarily rely upon 
the less efficient metabolic program of glycolysis (87, 88). Since 
glycolysis is less efficient (there are two ATP molecules pro-
duced per molecule of glucose used in glycolysis versus 36 ATP 
molecules produced per molecule of glucose used in oxidative 
phosphorylation) activated CD8+ T cells depend upon very high 
rates of glycolysis to meet their energy demands and thus require 
large amounts of glucose to be available in their surrounding 
environment. Signaling downstream of CD28 co-stimulation 
activates PI3K/Akt signaling, leading to increased expression of 
genes necessary for the high glycolytic rate required by activated 
CD8+ T  cells (89). The influence of the tumor microenviron-
ment, which is glucose deficient due to the rapid proliferation 
and energy demands of tumor cells, on metabolism of antitumor 
effector CD8+ T  cells has been the focus of numerous recent 
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studies. Here, we will discuss the influence of PD-L1 signaling on 
the metabolism of antitumor effector CD8+ T cells.
It has long been appreciated that signaling downstream 
of PD-1 ligation by PD-L1 leads to impaired glycolysis due to 
PD-1-mediated inhibition of CD28 signaling (8). In a graft-
versus-host disease model, Saha et al. demonstrated that wild-
type donor T cells in syngeneic PD-L1-deficient hosts exhibited 
increased rates of glycolysis, indicating that PD-L1 signaling 
serves to inhibit glycolysis downstream of PI3K/Akt signaling 
(90). Among the necessary genes for glycolysis is the glucose 
transporter, Glut1, expressed at very high levels on the surface 
of activated CD8+ T cells (91). Syngeneic CD8+ T cells in PD-L1 
deficient hosts exhibit significantly increased levels of Glut1 
expression on the cell surface (90). Tumor microenvironments, 
in addition to having limited glucose, often have high levels of 
PD-L1 expression, both of which impair glycolysis in effector 
CD8+ T  cells (92). In a mouse model of solid tumors, when 
PD-L1/PD-1 signaling was blocked, intratumoral CD8+ T cells 
regained their ability to perform glycolysis and effector func-
tions, which led to tumor regression (93). These data indicate 
that PD-L1/PD-1 checkpoint blockade therapies, in addition to 
lifting inhibition of effector function of antitumor CD8+ T cells, 
additionally contribute to the regaining of metabolic fitness by 
antitumor CD8+ T cells.
In addition to the priming phase of T cell responses, antigen-
presenting cells regulate effector T  cell function at peripheral 
tissues, including inside tumors. Blood monocyte-derived 
myeloid dendritic cells have cell-surface PD-L1, the expression 
of which is increased by the hypoxic tumor microenvironment 
(94). Hypoxia-inducible factor-1α caused a rapid, dramatic, and 
selective upregulation of PD-L1 on splenic myeloid-derived 
suppressor cells (MDSCs) along with macrophages, dendritic 
cells, and tumor cells (95). Among the subsets of MDSC, it seems 
monocytic-MDSCs (CD14+HLA-DRlow) express higher PD-L1 
than other subsets in patients with the diffuse large B-cell lym-
phoma (96). PD-L1 expressed by tumor-associated MDSCs and 
macrophages provides an immunosuppressive environment that 
fosters cancer progression, and blockade of PD-L1 restored the 
function of tumor-reactive T cells (97). Accordingly, a combina-
tion of checkpoint blockade therapy with reagents that inactivate 
MDSCs is effective in overcoming resistance to checkpoint 
blockade therapy (98). PD-1 is expressed by tumor-associated 
macrophages, and signaling downstream of the PD-L1/PD-1 
interaction inhibits phagocytosis, a crucial step in innate immu-
nity to cancer (99). PD-1 expressed by monocytes induces IL-10 
production and impairs T  cell activation (100). It is possible 
that the co-expression of PD-1 and PD-L1 by macrophages and 
monocytes may form a regulatory circuit across innate and adap-
tive immune cells.
CONCLUDiNg ReMARKS
Programmed death-ligand 1/PD-1 checkpoint blockade thera-
pies are becoming an increasingly common treatment option 
for patients with a variety of tumors. As their use becomes 
more widespread, it continues to be important that we fully 
understand the mechanism of action of therapeutic antibodies 
and their target molecules, as well as develop reliable methods 
to identify patients most likely to benefit from PD-L1/PD-1 
checkpoint blockade therapies. When the interaction between 
PD-L1+ tumor cells and PD-1+ CD8+ T cells, the intended target 
for PD-L1/PD-1 checkpoint blockade therapies, is disrupted, the 
result is reinvigoration of the antitumor CD8+ T  cell response 
and enhanced CD8+ T cell-mediated killing of tumor cells. As 
interactions between PD-L1 and PD-1 are not limited to the 
tumor microenvironment, it is important to consider the influ-
ence of the PD-L1/PD-1 interaction that occurs in other contexts. 
Based on the findings reviewed here, it can be concluded that 
PD-L1/PD-1 checkpoint blockade therapies likely enhance the 
priming of antitumor CD8+ T cells, but may limit the survival 
of antitumor CD8+ T  cells by interfering with a CD8+ T  cell 
intrinsic pro-survival/antiapoptotic role for PD-L1 signaling. 
This context-dependent role for the PD-L1/PD-1 interaction may 
be responsible in part for the unpredictable patient responses to 
PD-L1/PD-1 checkpoint blockade therapies.
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